A Phase 1 b Study of the Selective HDAC Inhibitor Mocetinostat in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma

Brief description of study

If you have been diagnosed with melanoma that cannot be surgically removed or has spread to other parts of your body, you may be qualified to participate in this phase 1b study evaluating the safety of the investigational drug Mocetinostat. together with ipilimumab and nivolumab for patients with advanced melanoma. The main goal of this study is to evaluate the safety of the combination of all three drugs when treating patients with unresectable Stage III or Stage IV melanoma.


Clinical Study Identifier: s17-00861
ClinicalTrials.gov Identifier: NCT03565406
Principal Investigator: Jeffrey S. Weber
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.